丹红注射液联合依达拉奉右莰醇治疗急性脑梗死的疗效

doi:10.3969/j.issn.1671-7171.2024.12.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1201 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨丹红注射液联合依达拉奉右莰醇治疗急性脑梗死(ACI)的疗效。【方法】98例ACI患者随机分为观察组和对照组,每组49例。对照组采用依达拉奉右莰醇治疗,观察组采用丹红注射液联合依达拉奉右莰醇治疗,比较两组患者治疗前后的神经功能[美国国立卫生院卒中量表(NIHSS)评分]及认知功能[简易认知状态评价量表(MMES)评分],血清泛素羧基末端水解酶L1(UCH-L1)、超敏C反应蛋白(hs-CRP)水平,生活能力及不良反应发生情况。【结果】观察组治疗后的NIHSS评分,以及血清UCH-L1、hs-CRP水平均低于对照组,MMES评分、生活能力评分均高于对照组(P<0.05)。观察组不良反应发生率为10.20%,与对照组的8.16%比较,差异无统计学意义(P>0.05)。【结论】丹红注射液联合依达拉奉右莰醇治疗ACI患者的疗效显著,可改善患者神经及认知功能,降低炎症因子水平,且不良反应发生较少。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郑春利
	杨军玲

关键词 ：脑梗死, 急性病, 丹红注射液, 依达拉奉, 治疗结果

Abstract：【Objective】 To investigate the efficacy of Danhong injection combined with Edaravone dextrocamphorol in the treatment of acute cerebral infarction (ACI). 【Methods】A total of 98 patients with ACI were randomly divided into the observation group and the control group, with 49 cases in each group. The control group was treated with Edaravone dexcamphorol, and the observation group was treated with Danhong injection combined with Edaravone dexcamphorol. The neurological function (NIHSS score) and cognitive function (Mini-mental State Examination, MMES) score, Ubiquitin carboxyl terminal hydrolase L1 (UCH-L1) ,hypersensitive C-reactive protein (hs-CRP) levels and living capacity and adverse reactions of the two groups were compared before and after treatment. 【Results】After treatment, NIHSS score, UCH-L1 level and hs-CRP level in the observation group were lower than those in the control group, and MMES score and life ability score were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 10.20%, which was not statistically significant compared with 8.16% in the control group (P>0.05). 【Conclusion】Danhong injection combined with Edaravone dextrocamphorol is effective in the treatment of ACI patients, which can improve the neurological and cognitive functions of patients, reduce the level of inflammatory factors, and have fewer adverse reactions.

Key words： Brain Infarction Acute Disease Danhong Zhusheye Edaravone Treatment Outcome

收稿日期: 2023-11-20

中图分类号:

R743.33

通讯作者: *E-mail:2507384223@qq.com

引用本文:

郑春利, 杨军玲. 丹红注射液联合依达拉奉右莰醇治疗急性脑梗死的疗效[J]. 医学临床研究, 2024, 41(12): 1893-1895.
ZHENG Chunli, YANG Junling. Curative Effect of Danhong Injection Combined with Edaravone Dextrocamphorol in the Treatment of Acute Cerebral Infarction. JOURNAL OF CLINICAL RESEARCH, 2024, 41(12): 1893-1895.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.12.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I12/1893

[1] 张亚萍. 急性脑梗死患者发生认知障碍的影响因素[J].河南医学研究,2023,32(3):467-470.
[2] 郝雅文. 急性脑梗死的治疗进展[J].天津药学,2021,33(4):66-69.
[3] 王东阳. 丹红注射液联合丁苯酞胶囊治疗短暂性脑缺血发作的疗效观察[J].基层医学论坛,2023,27(4):66-68.
[4] 刘前,邓倩,周静,等. 依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J].中国老年学杂志,2023,43(2):276-279.
[5] 赵建国, 高长玉, 顼宝玉, 等. 脑梗死和脑出血中西医结合诊断标准(试行)[J].中国中西医结合杂志, 2006, 26(10):948-949.
[6] 侯东哲,张颖,巫嘉陵,等.中文版美国国立卫生院脑卒中量表的信度与效度研究[J].中华物理医学与康复杂志,2012,34(5):372-374.
[7] 王杰.丁苯酞序贯治疗对急性脑梗死并认知障碍的作用及对患者NIHSS、mRS、ADL的影响[J].吉林医学,2022,43(5):1313-1315.
[8] 梁菊萍,杨旸,董继存. 急性脑梗死患者流行病学调查及危险因素[J].中国老年学杂志,2021,41(12):2484-2487.
[9] 何雪婷,马进. 缺血性中风的中医证治探析[J].中国民间疗法,2023,31(6):1-4.
[10] 王允明,王爱菊,陈海燕. 依达拉奉对急性脑梗死的治疗效果[J].实用医学杂志,2006,22(23):2760.
[11] FENG X J, LI Y, WANG Y N, et al. Danhong injection in cardiovascular and cerebrovascular diseases:pharmacological actions, molecular mechanisms, and therapeutic potential[J].Pharmacol Res,2019,139:62-75.
[12] 李一才,韩国胜,窦寿坦,等. 依达拉奉右莰醇联合丁苯酞注射液治疗急性进展性脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(6):763-767.
[13] 张园园,谭忠兵,管义祥. 血清UCH-L1水平与急性脑梗死的诊断及预后关系探讨[J].中国实验诊断学,2022,26(6):864-868.
[14] FENG C, WAN H F, ZHANG Y Y, et al. Neuroprotective effect of danhong injection on cerebral ischemia-reperfusion injury in rats by activation of the PI3K-Akt pathway[J].Front Pharmacol,2020,11:298.